NEOGENOMICS INC

NeoGenomics, Inc. provides oncology diagnostic testing and consultative services. These services include technical laboratory services and professional interpretation of test results by licensed physicians or molecular experts specializing in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. As of December 31, 2025, NeoGenomics operated College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments of 1988 (CLIA) certified laboratories in Fort Myers, Florida; Aliso Viejo and Carlsbad, California; Durham, North Carolina; Ramsey, New Jersey; and Houston, Texas. It also operated an International Organization for Standardization (ISO) certified, CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. Additionally, the company has several small, non-processing laboratory locations across the United States for analysis services. NeoGenomics offers Cytogenetics (karyotype analysis), which is the study of normal and abnormal chromosomes and their relationship to disease, involving the analysis of chromosome structure to identify changes from normal patterns. These studies provide diagnostic, prognostic, and occasionally predictive information for patients with hematological malignancies. The company also offers Fluorescence In-Situ Hybridization (FISH), a molecular cytogenetic technique that detects and localizes specific DNA sequences and genes on chromosomes using fluorescent probes visualized by fluorescence microscopy.